Pulmonary paracoccidioidomycosis in AhR deficient hosts is severe and associated with defective Treg and Th22 responses

Eliseu Frank de Araújo¹, Nycolas Willian Preite³,³, Marc Veldhoen², Flávio Vieira Loures¹,³ & Vera Lúcia Garcia Calich¹*

AhR is a ligand-activated transcription factor that plays an important role in the innate and adaptive immune responses. In infection models, it has been associated with host responses that promote or inhibit disease progression. In pulmonary paracoccidioidomycosis, a primary fungal infection endemic in Latin America, immune protection is mediated by Th1/Th17 cells and disease severity with predominant Th2/Th9/Treg responses. Because of its important role at epithelial barriers, we evaluate the role of AhR in the outcome of a pulmonary model of paracoccidioidomycosis. AhR−/− mice show increased fungal burdens, enhanced tissue pathology and mortality. During the infection, AhR−/− mice have more pulmonary myeloid cells with activated phenotype and reduced numbers expressing indoleamine 2,3 dioxygenase 1. AhR-deficient lungs have altered production of cytokines and reduced numbers of innate lymphoid cells (NK, ILC3 and NCR IL-22). The lungs of AhR−/− mice showed increased presence Th17 cells concomitant with reduced numbers of Th1, Th22 and Foxp3+ Treg cells. Furthermore, treatment of infected WT mice with an AhR-specific antagonist (CH223191) reproduced the main findings obtained in AhR−/− mice. Collectively our data demonstrate that in pulmonary paracoccidioidomycosis AhR controls fungal burden and excessive tissue inflammation and is a possible target for antifungal therapy.

AhR is a ligand-activated cytosolic transcription factor with known involvement in the metabolism of xenobiotic compounds. It mediates the toxic effects of man-made aryl hydrocarbons including 2,3,7,8-tetrachlorodibenzo-p-dioxin (also known as TCDD or Dioxin)¹ but can also be activated by a diverse set of endogenous and exogenous ligands². In steady state, AhR remains in the cytoplasm as part of an inactive complex composed of several chaperone proteins³. Upon ligand binding, AhR is released, translocate to the nucleus and heterodimerizes with its partner AhR Nuclear Translocator (ARNT). The heterodimer can bin genomic regions containing its binding motif, thereby inducing the transcription of target genes including detoxifying enzymes of the cytochrome P₄₅₀ family⁴ and the AhR repressor that disrupts the AhR/ARNT complex and attenuates AhR signaling. In the nucleus, AhR can interact with several transcription factors that regulate its activity³. The degree of AhR activation may dependent on the structure and receptor affinity of the ligand. Several tryptophan (Trp) degradation products such as Kynurenine (Kyn), produced by the enzymatic action of indoleamine 2,3 dioxygenase (IDO-1) and 6-formylindolo[3,2-b] carbazole (FICZ), a tryptophan condensation product, are well known AhR ligands⁵,⁶. AhR is expressed by cells of the innate and adaptive immune system and participates in the control of cell proliferation, differentiation and cytokine secretion⁷⁻¹⁰. In 2008, different laboratories showed that AhR contributes to the differentiation of Th17 and regulatory T cells (Treg)⁸⁻¹⁰. Interestingly, two different AhR ligands (TCDD and FICZ) were shown to modulate the severity of experimental autoimmune encephalomyelitis in opposing directions⁸,¹⁰. These findings led several investigators to study the role of AhR in diverse autoimmune, neoplastic and infectious diseases. However, the effects of AhR activation were not homogeneous due to the diverse AhR ligands used, type of pathology studied, and treatment protocols used¹¹⁻¹⁴.

¹Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil. ²Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal. ³Instituto de Ciência E Tecnologia, Universidade Federal de São Paulo, São José dos Campos, SP, Brazil. *email: vlcalich@icb.usp.br
Many studies have tested the influence of AhR activity and its ligands in infectious processes\textsuperscript{12}. Several reports have demonstrated the regulatory activity of AhR on viral\textsuperscript{13}, bacterial\textsuperscript{14,15}, protozoal\textsuperscript{16}, parasitic\textsuperscript{17} and fungal\textsuperscript{18-22} infections. For example, in \textit{Candida albicans} and \textit{Aspergillus fumigatus} infections, the IDO enzyme was shown to concomitantly reduce fungal loads mediated by Trp starvation and inflammatory reactions due to the expansion of Treg cells via Kyn-induced AhR activation\textsuperscript{20-22}. Besides Th17/Treg cell differentiation\textsuperscript{21,26}, agonist-activated AhR was shown to be linked with IL-22 production\textsuperscript{23,24}. Indeed, at mucosal sites infected with \textit{C. albicans} AhR was shown to control IL-22 transcription/production that provides a protective phenotype in intestinal epithelial cells\textsuperscript{22}. AhR was also involved in the expansion and differentiation of innate lymphoid cells (ILCs), a family of immune cells that do not express rearranged antigen receptor but can be organized with phenotypes similar to T cells\textsuperscript{22}. AhR-deficiency increases the number of pulmonary \textit{CD11c}+ leukocytes with activated phenotype\textsuperscript{23}. C57BL6/J WT and AhR-/- mice were infected as previously described, their lung cells obtained after 96 h, 2 and 10 weeks of infection and analyzed for expression of surface molecules by flow cytometry. CD11c+ myeloid cells were chosen because this cell marker is highly expressed in dendritic cells and our previous studies have shown their high involvement in AhR/IDO expression\textsuperscript{26,28,29}. Thus, lung CD11c+ cells were assessed for the expression of IA\textsuperscript{3}, CD86 and CD80 as activation markers\textsuperscript{31}. As can be seen in Fig. 2A, AhR-/- mice presented increased influx of CD11c+ lung myeloid cells expressing MHC class II molecules (IA\textsuperscript{3}) and costimulatory (CD80 and CD86) molecules (Fig. 2B–D) indicating a higher activated phenotype than those of control WT mice.

\textit{P. brasiliensis} infection results in three well defined outcomes: the subclinical infection, where no symptoms are present but might evolve towards a progressive, clinically manifested disease; the acute form, which generally affects young individuals of both sexes, is an overt and severe process evidenced by involvement of multiple organs; the chronic form, the most common (90%) clinical presentation observed in older individuals, predominantly men, presents heterogeneous clinical manifestations, ranging from isolated pulmonary or epithelial lesions (unifocal form) to systemic involvement (multifocal form)\textsuperscript{32}. Similar to other systemic mycoses, immunoprotection in PCM is mediated by Th1/Th17 responses that are controlled by the anti-inflammatory activity of Treg cells. The severe forms are associated with Th2/Th9 responses and uncontrolled fungal growth associated with severe tissue pathology mediated by dysregulated Th17/Treg cell immunity\textsuperscript{33}. Our recent studies have demonstrated that \textit{P. brasiliensis} infection induces a marked IDO-1 expression that mediates Trp catabolism resulting in increased Kyn production and AhR activation\textsuperscript{36}. \textit{P. brasiliensis} uses two distinct mechanisms to trigger IDO-1 expression that is dependent on the genetic pattern of hosts. In susceptible mice (B10.A), IDO-1 is induced by IFN-\gamma and predominantly exhibits enzymatic activity. In resistant (A/J) mice, activation of dendritic cells mediated by TGF-\beta results in IDO-1 phosphorylation that confers a signaling property to the molecule and a tolerogenic profile for plasmacytoid dendritic cells\textsuperscript{36,37}. Our studies have also demonstrated that IDO-1 and AhR are mutually regulated and influence the Th17/Treg cell balance\textsuperscript{38,39}. Indeed, in pulmonary PCM absence of IDO-1 expression leads to a robust reduction of AhR expression that results in uncontrolled fungal growth associated with severe tissue pathology mediated by dysregulated Th17/Treg cell immunity\textsuperscript{39}. However, the exact role of AhR in the immunoregulation of pulmonary PCM was not still defined. Using AhR-/- mice, we could demonstrate that AhR expression is important for the control of fungal growth and differentiation of ILCs and T cells. Pulmonary PCM in AhR-/- mice is characterized by progressive fungal growth and dissemination despite enhanced Th17 cell immunity that, instead of immunoprotection, appears to be involved in tissue damage and disease severity. The robust influence of AhR in IL-22 producing cells was also demonstrated: a decreased migration of CD4+ CD44+ CD24- CD25+ T lymphocytes. ILC3 and NCR+ IL-22+ ILCs were observed in the lungs AhR-/- mice. Importantly, the main findings with AhR-/- mice were validated with an AhR-specific antagonist, the drug CH223191, indicating that immunomodulation of AhR could be used in future immunotherapeutic procedures.

Results

Absence of AhR increases fungal loads and tissue pathology reducing the survival of \textit{P. brasiliensis} infected mice. The influence of AhR on the fungal burden, recovered 96 h, 2 and 10 weeks after infection with 1 \times 10^6 \textit{P. brasiliensis} yeasts, was assessed by a CFU assay. These time points were used to better assess some features of innate (96 h), and early (2 weeks) and late phases (10 weeks) of adaptive immunity. Compared to WT controls, AhR-/- mice showed higher pulmonary and hepatic fungal loads (Fig. 1A). The levels of pulmonary NO after 96 h, 2 and 10 weeks of infection was also higher in AhR-/- mice (Fig. 1A), indicating that fungicidal ability in the absence of AhR is reduced, despite increased levels of nitric oxide that is considered a major IDO-1 and AhR are mutually regulated and influence the Th17/Treg cell balance38,39. Indeed, in pulmonary PCM absence of IDO-1 expression leads to a robust reduction of AhR expression that results in uncontrolled fungal growth associated with severe tissue pathology mediated by dysregulated Th17/Treg cell immunity39. However, the exact role of AhR in the immunoregulation of pulmonary PCM was not still defined. Using AhR-/- mice, we could demonstrate that AhR expression is important for the control of fungal growth and differentiation of ILCs and T cells. Pulmonary PCM in AhR-/- mice is characterized by progressive fungal growth and dissemination despite enhanced Th17 cell immunity that, instead of immunoprotection, appears to be involved in tissue damage and disease severity. The robust influence of AhR in IL-22 producing cells was also demonstrated: a decreased migration of CD4+ CD44+ CD24- CD25+ T lymphocytes. ILC3 and NCR+ IL-22+ ILCs were observed in the lungs AhR-/- mice. Importantly, the main findings with AhR-/- mice were validated with an AhR-specific antagonist, the drug CH223191, indicating that immunomodulation of AhR could be used in future immunotherapeutic procedures.

AhR-deficiency increases the number of pulmonary CD11c+ leukocytes with activated phenotype. C57BL6/J WT and AhR-/- mice were infected as previously described, their lung cells obtained after 96 h, 2 and 10 weeks of infection and analyzed for expression of surface molecules by flow cytometry. CD11c+ myeloid cells were chosen because this cell marker is highly expressed in dendritic cells and our previous studies have shown their high involvement in AhR/IDO expression26,28,29. Thus, lung CD11c+ cells were assessed for the expression of IA3, CD86 and CD80 as activation markers31. As can be seen in Fig. 2A, AhR-/- mice presented increased influx of CD11c+ lung myeloid cells expressing MHC class II molecules (IA3) and costimulatory (CD80 and CD86) molecules (Fig. 2B–D) indicating a higher activated phenotype than those of control WT mice.
Absence of AhR reduces numbers of IDO-1-expressing myeloid cells. Previous reports demonstrating that immunoregulation exerted by IDO-1 on innate and adaptive immunity depends on the activation
of the AhR, led us to examine the numbers of CD11c⁺ cells expressing IDO-1 and AhR in AhR⁻/⁻ and WT infected mice. Lung leukocytes were obtained 96 h, 2 and 10 weeks after infection, and the number of IDO-1⁺ and AhR⁺ cells was determined by flow cytometry. Compared with WT controls, a significant reduction of IDO-1⁺CD11c⁺ cells was detected in AhR⁻/⁻ mice. As expected, only WT mice expressed AhR⁺ cells that increased in the course of infection (Fig. 2E, F).

Characterization of cytokines in CD11c⁺ lung leukocytes from infected AhR⁻/⁻ and control mice. After 96 h, 2 and 10 weeks of infection lung leukocytes were obtained from infected AhR⁻/⁻ and WT mice and analyzed by flow cytometry for the presence of intracellular cytokines (IL-12, TNF-α, IL-1β, IL-6, TGF-β and IL-10) in CD11c⁺ gated cells. A very homogeneous pattern was observed: in AhR⁻/⁻ mice a reduced number of CD11c⁺ cells expressing pro-inflammatory (IL-12, TNF-α and IL-1β) and anti-inflammatory (TGF-β and IL-10) cytokines was seen in the lungs of AhR⁻/⁻ mice. As expected, only WT mice expressed AhR⁺ cells that increased in the course of infection (Fig. 2E, F).

Absence of AhR decreases the presence of NK, ILC3 and NCR IL-22 innate lymphoid cells (ILCs) in lungs of P. brasiliensis infected mice. The expression of AhR is important for the maintenance, survival, and function of ILC3. In addition, AhR cooperates with RORγt to induce IL-22 transcription²⁵,²⁸,⁴², a fact that led us to phenotypically characterize these cells in P. brasiliensis infected WT and AhR⁻/⁻ mice. Therefore, ILC subpopulations were categorized by their expression of specific surface molecules and transcription fac-
tors as described in material and methods. NK cells were classified as Lin⁺CD45⁺NK1.1⁺ NKp46⁺Eomes⁺, ILC1 as CD45⁺Lin⁻CD127⁺Tbet⁺, ILC2 as CD45⁺Lin⁻CD127⁺Gata3⁺, ILC3 as CD45⁺Lin⁻CD127⁺RORC⁺ and NCR⁺IL-22⁺ as CD45⁺Lin⁻CD127⁺RORC⁺NKp46⁺IL-22⁺. As can be seen in Fig. 4, in the whole course of the infection a marked decrease in the number of NK, ILC3 and NCR IL-22 lymphocytes was observed in the lungs of AhR⁻/⁻. No differences in ILC1 and ILC2 were observed between AhR⁻/⁻ and their WT counterparts (Fig. 4).

**Influence of AhR on gene expression in lungs of P. brasiliensis infected mice.** The expression of mRNA for some cytokines (ifn-γ, tnf-α, il-6, il-17 and il-22), IDO-1 enzyme (ido), and transcription fac-

---

**Figure 3.** Absence of AhR reduces the number of pulmonary CD11c⁺ cells expressing cytokines, except for IL-6⁺ cells. Expression of cytokines (IL-12, TNF-α, IL-1β, IL-6, TGF-β and IL-10) by CD11c⁺ lung leukocytes of AhR⁻/⁻ and WT mice infected i.t. with 1 × 10⁶ P. brasiliensis yeasts. The presence of cytokines was assessed using fluorochrome labelled specific monoclonal antibodies by flow cytometry at the CD1c⁺ cell gates (see Figure S1). Data represent the mean ± SEM of 3 experiments using 5 animals per group. The asterisk represents a statistically significant difference (*P<0.05 and **P<0.01).
and WT controls were evaluated by flow cytometry at weeks 2 and 10 following infection. CD8+CD44highCD62Llow, respectively) T cells (Fig. 7B).

NK cells were then classified as Lin+CD45+NK1.1+NKp46+Eomes+, ILC1 as CD45+Lin−CD127+Tbet+, ILC2 as CD45+Lin−CD127+Gata3+, ILC3 as CD45+Lin−CD127+RORC+ and NCR+IL-22+. The cell surface and intracellular markers were measured by flow cytometry. 50,000 cells were counted, and the data expressed by number of positive cells. Data are expressed as M±SEM and are representative of three independent experiments using 5 mice of each mouse strain per group (*P<0.05; **P<0.01 and ***P<0.001).

### Influence of AhR on the production of pulmonary cytokines.

The lung homogenates of WT and AhR−/− mice were collected after 96 h, 2 and 10 weeks of infection and used to evaluate the presence of cytokines (IL-12, TNF-α, IL-1β, IL-6, IL-23, IL-2, IFN-γ, IL-4, IL-17, IL-22, TGF-β, IL-10, IL-27, and IL-35). As can be seen in Fig. 6, increased levels of TNF-α, IL-6, IL-2, and IL-4 were detected in the lungs of AhR deficient mice at all time points evaluated. IL-17 appeared in higher levels at weeks 2 and 10 following infection. In contrast, IL-1β, IFN-γ, IL-22, IL-10, IL-27 and IL-35 were present in lower levels in the lungs of these mice at all post-infection periods assessed. Interestingly, IL-1β was the pro-inflammatory cytokine most noticeably reduced in the lungs of AhR deficient mice. TGF-β was the only cytokine in the group of suppressive or inhibitory cytokines that was not affected by the absence of AhR expression. All other inhibitory cytokines involved in the development or activity of Tr1 and Treg (IL-27, IL-10 and IL-35) cells were detected in reduced concentrations in the lungs of AhR deficient mice.

### Absence of AhR increases Th17 cells but reduces Th1, Th22 and Treg cells in the lungs of P. brasiliensis infected mice.

The number and phenotype of T cells that were present the lungs of AhR−/− mice and WT controls were evaluated by flow cytometry at weeks 2 and 10 following infection. A higher number of naive and activated CD4+ (CD4+CD44lowCD62Lhigh and CD4+CD44highCD62Llow, respectively) T lymphocytes were observed in the lungs of AhR deficient mice at both post-infection periods studied (Fig. 7A). The same was observed for naive and activated CD8+ (CD8+CD44lowCD62Lhigh and CD8+CD44highCD62Llow, respectively) T cells (Fig. 7B).

When the Th1, Th2, Th17 and Th22 subpopulations were characterized (Fig. 7C), a reduced number of Th1 cells (CD4+IFN-γ+) and Th22 (CD4+IL-22+) cells were found in the lungs of AhR−/− mice in comparison with the WT controls. In contrast, Th17 (CD4+IL-17+) lymphocytes were observed in increase numbers in AhR deficient mice. When the number of regulatory CD4+CD25+FoxP3+ T lymphocytes (Tregs) was assessed, a significant decrease was detected in the lungs of AhR deficient mice at both time points analyzed (Fig. 7D). No differences were found in Th2 cells (Fig. 7C).

### Treatment of P. brasiliensis infected mice with an AhR-specific antagonist (CH223101) reproduces the main findings in AhR−/− mice.

Finally, we extended the results obtained with AhR−/− mice by assessing the antagonist effects of CH223191 in pulmonary PCM. Mice were treated as described in Material and Methods, infected with 1 × 10⁶ fungal cells and studied at 96 h and 2 weeks after infection. Treatment with CH223191 increased the fungal load at both post-infection periods studied (Fig. 8). At week 2, CD11c+ leukocytes showed increased numbers of MHC class II molecules (IAβ), CD40, CD80 and CD86. However, the number of CD11c+ cells expressing IDO-1 or AhR was significantly reduced. Characterizing the main T cell phenotypes present in the lungs of CH223191-treated mice, an augmented number of Th17 cells was concomitant with a reduction in Th1, Th22 and Foxp3+ Treg cells (Fig. 8). These findings reproduce the main phenotypes observed in AhR−/− mice, further evidencing the immunomodulatory activity of AhR in pulmonary PCM.

### Discussion

Once considered a mediator in the toxic response to dioxin, the AhR was subsequently described as an important regulator of the immune response, including the immunity against infectious agents. Besides the induction of detoxifying enzymes, AhR modulates the differentiation and activity of innate and adaptive immune cells, markedly influencing the outcome of infectious processes. Indeed, here we could demonstrate that AhR has an important regulatory role in pulmonary PCM. The Fig. 9 summarizes the main findings of AhR deficiency on...
the innate and adaptive phases of immunity in *P. brasiliensis* infected mice. The lack of AhR expression reduces cytokines, IDO-1 expression and Kyn synthesis by pulmonary DCs. This altered pulmonary microenvironment leads to defective innate immunity mechanisms with reduced participation of NK, ILC-3 and NCR-IL-22 cells. At the adaptive phase of immunity that subsequently develops, the lack of AhR leads to reduced expansion of the Th1, Th22 and Treg cells associated with increased Th17 development, whose pro-inflammatory activity is only partially controlled by the reduced number of Treg cells. The diminished IDO activity also promotes increased Trp availability that facilitates fungal growth. Altogether, the increased fungal loads and the inefficient effector mechanisms of immunity possibly contribute to the enhanced pulmonary pathology and elevated mortality rates developed by AhR−/− mice. It is important to comment that the inclusion of additional controls showing base lines differences between WT and AhR deficient mice would improve data analysis. However, the limitations imposed by the difficulty of obtaining a sufficient number of AhR−/− mice, as most fetuses do not develop due to the serious genetic errors associated with this deficiency, and the restriction to the use of large number of animals imposed by the ethics committee for animal use justify the experimental design here employed. Nevertheless, the differences here observed were probably due to the genetic differences associated with AhR deficiency, since both AhR−/− and WT mice belong to the same C57BL/6 strain. Furthermore, experiments with the AhR antagonist reproduced the main findings observed in AhR deficient mice, indicating that the different responses observed were linked to AhR expression.

An important finding in AhR biology was the mutual control exerted by AhR and IDO-1 expression44–46, a finding here confirmed in pulmonary PCM. This enzyme has been studied for its antimicrobial ability mainly

Figure 5. Absence of AhR alters mRNA levels of cytokines, transcription factors and the IDO enzyme. The relative expression of mRNA of pro- and anti-inflammatory cytokines (IFN-γ, TNF-α, IL-6, IL-17, IL-22, TGF-β and IL-10), transcription factors (Tbet, RORc, Foxp3 and GATA-3) as well as the IDO enzyme was determined by Real-Time PCR in total lung cells of AhR−/− and WT mice after 96 h, 2 and 10 weeks of *P. brasiliensis* infection. Data are shown as M ± SEM from three independent experiments using 5 mice per group. The asterisk represents a statistically significant difference (*P < 0.05 and **P < 0.01, ***P < 0.001).
mediated by Trp starvation\textsuperscript{47} and also by the immunoregulatory activity of kynurenines\textsuperscript{48–50}. In fungal infections, the importance of the IDO-1/Kyn/AhR axis in the generation of Treg cells and tolerogenic activities of DCs was demonstrated\textsuperscript{37,51,52}. In pulmonary PCM, our group has shown a profound interconnection between IDO-1 and AhR expression where a balanced activation of these mediators was connected with the control of fungal immunity and disease tolerance\textsuperscript{36–39}.

Fundamental studies have revealed that AhR controls several mechanisms of immunity, due to its influence in innate immunity cells (ILC3, ITi, NCR IL-22, macrophages, DCs) and cells of adaptive immunity (Treg, Th17, Th22)\textsuperscript{8–10}. Here we could demonstrated that in pulmonary PCM the lack of AhR expression modified the innate and adaptive phases of immunity resulting in increased fungal burden, increased tissue pathology and mortality rates of \textit{P. brasiliensis} infected mice. Analogous results were observed in \textit{Listeria monocytogenes} but not in \textit{Trypanosoma cruzi} infected AhR\textsuperscript{−/−} mice. Interesting, in \textit{T. cruzi} infection, an increased NO production by AhR-deficient mice was concomitant with reduced pathogen loads\textsuperscript{53}, an observation not reproduced in our study. Despite the increased NO levels detected in AhR\textsuperscript{−/−} mice, an increased fungal burden was observed, suggesting that in pulmonary PCM the Trp depletion mediated by the enzymatic activity of IDO-1 exerts a more efficient fungicidal mechanism than that mediated by NO.

Figure 6. Absence of AhR alters the levels of cytokines in the lung. Pro- and anti-inflammatory cytokines were measured by ELISA in lung homogenates of \textit{P. brasiliensis} infected AhR\textsuperscript{−/−} and WT mice obtained 96 h, 2 and 10 weeks after infection. Data show M ± SDM of one experiment using 5 mice per group. The asterisk represents a statistically significant difference (*\textit{P} < 0.05 and **\textit{P} < 0.01, ***\textit{P} < 0.001).
The lack of AhR resulted in decreased numbers of pulmonary CD11c+ cells expressing pro-inflammatory (IL-12, TNF-α and IL-1β) and anti-inflammatory (TGF-β and IL-10) cytokines, except for IL-6 producing cells for which were found in increased numbers. This reduction in cytokines production occurs despite the increased numbers of CD11c+ cells expressing activation markers (IAβ, CD80, CD86). However, this diverse activation profile was possibly involved in the reduced expansion of some T cell subsets (Th1, Th22, Treg) and the increased proliferation of others (Th17). In agreement, IL-6 that is a positive regulator of Th17 cells via STAT3 activation8–10, may have contributed to the increased expansion of Th17 cells detected in AhR−/− mice. In addition, AhR-deficient mice have also a significant reduction in the number of CD11c+IL-1β+ cells as well as in the levels of IL-1β present in lung homogenates. In pulmonary PCM the activation of NLRP3 inflammasome and IL-1β synthesis play an important role in the innate and adaptive phases of immunity54–57, therefore the reduction in IL-1β could have contributed to the reduced fungicidal ability of macrophages and DCs but not to the enhanced Th17 activation here described. Hughes et al.38 have elegantly demonstrated that IL-1β deficiency is associated with reduced expansion of IL-22+NKp46+ (NCR IL-22) cells. They showed that conventional DC-derived IL-1β preserves and expands IL-1R1hi IL-22+AhR+ immature NK cells, potentially influencing mucosal innate immunity during infection. The reduced presence of NCR IL-22+ cells here detected may be associated with the deficient

Figure 7. Absence of AhR increases the presence of Th17 cells into the lungs but reduces Th1, Th22 and Treg cells. The lung cells were obtained as described in Material and Methods and labeled with antibodies conjugated to different fluorochromes. For T cells phenotyping the lung infiltrating leukocytes were gated by FSC/SSC analysis and then gated for CD4+ or CD8+ expression. The expression of CD44 and CD62L was then evaluated in CD4+ and CD8+ T cells (for gates strategy see figures S2 and S3). (A) CD4+CD44lowCD62Lhigh and CD4+CD44highCD62Llow were considered naive and activated CD4 cells, respectively. (B) CD8+CD44lowCD62Lhigh, CD8+CD44highCD62Llow were considered naive and activated CD8 cells, respectively. (C) For Th cell subsets, cells were gated for CD4+ expression and then for intracellular expression of IFN-γ, IL-4, IL-17 and IL-22 (gate strategy is shown in figure S4 B). (D) For Treg cells, CD4 gated cells were then analyzed for CD25 and Foxp3 expression (gate strategy in figure S4 A). 100,000 cells were acquired on FACS CANTO II and subsequently analyzed by FlowJo software. Data are expressed as M ± SEM of three independent experiments using 5 mice per group. The asterisk represents a statistically significant difference (*P < 0.05 and **P < 0.01, ***P < 0.001.)
IL-1β production but the absence of AhR, that is fundamental to the expansion of IL-22 producing cells, was possibly the main mechanism responsible for the reduced numbers of NCR IL-22+ cells observed. The lungs of AhR−/− mice presented lower number of CD11c+TGF-β+ cells than did WT mice. TGF-β plays an important role in the differentiation of Th17 and Treg cells and the reduced synthesis of TGF-β and IL-1β by AhR−/− mice was unexpectedly accompanied by the enhanced secretion of IL-17, elevated number of Th17 cells and increased RORγt mRNA expression. These findings indicate that increased Th17 associated markers could have been positively modulated by the increased IL-6 production and STAT3 signaling as previously demonstrated. In addition, the increased Th17 expansion could be attributed to the increased fungal loads detected in AhR−/− mice. The reduced presence of myeloid cells expressing intracellular IL-10 and TGF-β and the diminished levels of IL-10 and IL-35 detected in lung supernatants of AhR−/− mice were concomitant with a potent reduction in the number of CD4+CD25+Foxp3+ Treg cells, possibly explaining the increased lung inflammation mediated by the elevated presence of Th17 cells. In addition, the low levels of IL-10 and IL-27 could also be linked to a diminished number of IL-10-producing Tr1 cells (not here characterized) that may influence the Treg and Th17 cells.

At the 2nd and 10th weeks of P. brasiliensis infection a reduced number of conventional NK, ILC3 and NCR IL-22 ILCs were found in the lungs of infected AhR. These findings are in partial agreement with the CD4+ T cell subsets and mRNA for cytokines and transcription factors observed in the AhR-deficient animals. Indeed, the reduced NCR IL-22, Th22 and IL-22 mRNA detected in AhR−/− mice clearly demonstrated that in pulmonary PCM IL-22 production is dependent on AhR expression. On the other hand, the increased Th17 and RORC mRNA here characterized suggest that the Th17 phenotype is highly dependent on the RORC transcriptional activity.

Figure 8. Pulmonary paracoccidioidomycosis can be immunomodulated by an AhR-specific antagonist (CH223191) that reproduces the main findings obtained in AhR-deficient mice. C57BL6/J WT mice were i.p. treated with vehicle (corn oil) or CH223191 at the dose of 20 mg/kg three times a week for 2 weeks, starting at the day of infection with 1 × 10⁶ P. brasiliensis yeasts. CFU counts were measured 96 h and 2 weeks after infection. The number of CD11c+ cells expressing membrane (IAb, CD80, CD86) and intracellular (IDO-1 and AhR) markers as well as the phenotype of CD4+ T cell subsets were measured by flow cytometry in lung leukocytes obtained at week 2 of infection. Data are shown as M ± SEM from three independent experiments using 4–5 mice per group. The asterisk represents a statistically significant difference (*P < 0.05 and **P < 0.01, ***P < 0.001).
factor. In contrast, the reduced numbers of ILC3 at the site of infection of AhR−/− mice, showed that these cells are much more dependent on AhR activity than Th17 cells.

Regarding adaptive immunity, AhR−/− mice showed an increased differentiation of Th17 cells concomitant with reduced expansion of Foxp3+ Treg cells. This finding could be correlated with the reduced IDO-1 expression that in the pulmonary model of PCM was seen to control tolerogenic DCs and Treg cells proliferation. On the other hand, contrasting the data with IDO-1−/− mice, a reduced number of CD4+IL-22+ cells were detected in AhR−/− mice. This result also agrees with the lower presence of IL-22 in lung homogenates of the AhR−/− mice, the reduced IL-22 mRNA expression and the significant reduction of IL-22-secreting ILC3 cells. Altogether, these data demonstrate that in pulmonary PCM IL-22 synthesis is highly dependent on the AhR transcription factor and, similarly with other fungal infections, IL-22 possibly exerts a protective role in pulmonary PCM.

Our previous studies have shown that Treg cells can be protective or deleterious to *P. brasiliensis* infected mice. At all post-infection times assayed, a reduced presence of Treg cells was here observed in line with reduced Foxp3 mRNA detected and the low levels of IL-10, TGF-β and IL-35, cytokines involved in the suppressive activity of this T cell subpopulation. Interestingly, the reduced TGF-β expression by myeloid cells and not the levels TGF-β mRNA of total lung cells were associated with the decreased Treg cells expansion that was insufficient to control lung inflammation.

Altogether, our data led us to suppose that the decreased presence of NK, ILC3 and NCR-IL-22 ILCs, concomitant with the reduced proliferation of Th1 and Th22 cells have possibly affected the IFN-γ mediated fungicidal mechanisms of phagocytes and the IL-22-mediated production of anti-microbial peptides by epithelial cells that play an important role in host defenses in fungal infections. Furthermore, these inefficient effector mechanisms appeared to have been potentiated by the decreased presence of Treg cells and their inhibitory effect on TH17-mediated tissue pathology.

Figure 9. Schematic representation of AhR deficiency in the innate and adaptive phases of immunity against *P. brasiliensis* infection. Compared with control WT mice (A), AhR−/− mice develop a defective innate and adaptive immunity (B). Absence of AhR expression alters the behavior of DCs that reduce IDO-1 expression and produce low levels of Kynurenines (Kyn). AhR deficiency also impairs the development of NK, ILC3 and NCR-IL-22 innate lymphoid cells involved in the synthesis of IFN-γ, IL-17 and IL-22 at the innate phase of immunity. At the adaptive phase of immunity, the reduced AhR activity results in decreased differentiation and expansion of Treg/Th1/Th22 cells but an increased proliferation of Th17 cells. In AhR−/− mice, the reduced IDO-1 activity allows high tryptophan availability that enhances fungal growth not adequately controlled by pro-inflammatory Th17 cells that possibly contribute with tissue pathology and increased mortality observed in deficient mice.
Our data using a specific AhR antagonist (CH223191) confirmed the important immunoregulatory role of AhR signaling in the control of pulmonary PCM. Similar to AhR-deficient mice, CH22319-treated WT mice presented increased fungal loads, increased numbers of myeloid cells expressing costimulatory molecules but reduced numbers containing IDO-1 or AhR proteins. In addition, an increased number of Th17 cells was concomitant with reduced presence of Th1, Th22 and Foxp3+ Treg cells in the lungs of treated mice. These data suggest that pulmonary PCM can be modulated by AhR ligands and are in agreement with those obtained in experimental vulvovaginal candidiasis where anti-fungal immunity and disease severity can be modulated by an AhR agonist via the IL-22-IL-18 crosstalk.

In conclusion, the data here reported and those previously published by our group allowed us to identify the importance of the IDO1/AhR axis in the control Treg/Th17/Th22 development and severity of pulmonary PCM. The absence of AhR expression unbalanced the innate and adaptive phases of immune responses resulting in a deleterious effect to the hosts where an unrestrained fungal growth is associated with uncontrolled inflammatory processes that result in tissue pathology. However, the data presented here open interesting immunotherapeutic perspectives, since the potent immune regulatory activity of AhR may be tentatively used alone or as adjunctive therapy to antifungals to modulate the immune response against *P. brasiliensis* infection and disease severity. We believe that immunomodulatory procedures are of actual importance, since treatment of PCM with antifungals is long lasting and has important side effects that lead to the non-adherence of patients and disease recurrence.

**Methods**

**Ethics statement.** The experiments were performed in strict accordance with the Brazilian Federal Law 11,794 establishing procedures for the scientific use of animals, and the State Law establishing the Animal Protection Code of the State of São Paulo. All efforts were made to minimize animal suffering. The procedures were approved by the Ethics Committee on Animal Experiments of the Institute of Biomedical Sciences of University of São Paulo (Proc.180/11/CEEA).

**Mice.** Eight- to 12-week-old male C57BL6/J WT and B6.129-Ahr<sup><small>-/-</small></sup>/J (AhR<sup><small>-/-</small></sup> mice) from Jackson Laboratories, originally provided by Dr. Marc Veldhoen and bred as specific pathogen free mice at the Isogenic Breeding Unit of the Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, were used throughout this study.

**Fungus and infection.** Yeast cells from the virulent *P. brasiliensis* 18 isolate (Pb18) was maintained by weekly cultivation in Fava Netto culture medium at 36°C and used on days 6–8 of culture. The viability of fungal cells, determined by Janus Green B vital dye (Merck), was always higher than 95%. Mice were anesthetized and submitted to intra-tracheal (i.t.) infection as previously described. Briefly, after intraperitoneal (i.p.) injection of ketamine and xylazine, animals were infected with 1 × 10<sup>6</sup> yeast cells, contained in 50 µL of PBS, by surgical i.t. inoculation, which allowed dispensing of the fungal cells directly into the lungs.

**CFU assays, mortality rates, and histological analysis.** The number of viable yeasts in lung and liver was determined by counting the number of colony-forming units (CFU) as previously described. Mortality studies were done with groups of 10–12 mice. Deaths were registered daily. For histological examinations, five-micrometer tissue sections were stained by hematoxylin–eosin for characterization of lesions and were silver stained (Grocott stain) for fungal evaluation. Morphometrical analysis was performed using a Nikon DXM 1200c camera and Nikon NIS AR 2.30 software. The areas of lesions were measured (in square micrometers) in 10 microscopic fields per slide in 5 mice per group as previously described. Results are expressed as the mean ± SEM of total area of lesions for each mouse.

**Assessment of leukocyte subpopulations and intracellular cytokines by flow cytometric analysis.** The lungs from *P. brasiliensis* infected WT and AhR<sup><small>-/-</small></sup> mice were collected after 96 h, 2 and 10 weeks of infection, digested enzymatically and lung leukocytes prepared as previously described. For cell-surface staining, lung cells were suspended at 1 × 10<sup>6</sup> cells/mL in staining buffer. Fc receptors were blocked with unlabeled anti-CD16/32 (eBioscience) and then stained for 30 min on ice with fluorophore-conjugated antibodies. For myeloid cells the following antibodies were used: anti-CD11c, CD40, CD80, CD86 and MHC-II (IAb<sup><small>+</small></sup>). For lymphocytes: anti-CD4, CD25, CD8, CD44, and CD62L. For ILCs characterization, lung leukocytes were first treated with anti-mouse lineage cocktail (Biolegend) containing antibodies to CD3, Ly6G/Ly6C, CD11b, CD45RB220, TER 119/erytroid cells, that react with T cells, B cells, monocytes, macrophages, NK cells and erythrocytes. Intracellular staining was conducted using the eBioscience Transcription Factor staining kit and specific antibodies for IL-17, IL-4, IFN-γ, IL-22, IL-1β, IL-12, TNF-α, IL-6, TGF-β, IL-10, FoxP3, IDO-1 and AhR. Cells were run on FACSCantoII (BD Biosciences) and a minimum of 50,000 events was acquired using a FACSDiva software (BD Biosciences). Cells were analyzed using FlowJo software (Tree Star).

**RNA isolation, cDNA synthesis and Real-Time quantitative polymerase chain reaction (RT-PCR).** RNA isolation from lungs of AhR<sup><small>-/-</small></sup> and control mice was done as previously described. RNA purity and concentration were assessed on a NanoDrop ND-1000 spectrophotometer. An amount of 1 µg total RNA was reverse transcribed in a 20 µL reaction mixture using the High Capacity RNA-to-cDNA kit (Applied Biosystems) following the manufacturer’s directions. The cDNA was amplified using TaqMan Universal PCR Master Mix (Applied Biosystems) and pre-developed TaqMan assay primers and probes (Ifng, Mm001168134_
Cytokines and NO detection. After 96 h, 2 and 10 weeks of infection, the lungs from *P. brasilienensis*-infected WT and AhR−/− mice were aseptically collected, disrupted, and the obtained supernatants were stored at −80 °C. Cytokines and NO levels were measured as previously described.80 A capture ELISA (enzyme-linked immunosorbent assay) was used to measure the levels of IL-12, TNF-α, IL-1β, IL-6, IL-23, IL-27, IFN-γ, IL-4, IL-17, IL-22, TGF-β, IL-10 and IL-35 with antibody pairs from eBioscience or PBL. Nitrilotrioxide production was quantified by a standard Griess reaction using a spectrophotometric plate reader (VersaMax, Molecular Devices). All determinations were performed in duplicate, and results were expressed as micro molar concentration of NO.

Treatment of mice with CH223291, an AhR-specific antagonist. Mice were treated with the AhR antagonist CH223191 (InvivoGen) as described by Kim et al.73 with minor modifications. In brief, male C57BL/6J WT mice were given vehicle (corn oil) or CH223191 (InvivoGen, 2-methyl-4-o-toluylophenyl-amide) at the dose of 20 mg/kg in corn oil three times a week for 2 weeks, starting at the day of infection. Mice were analyzed after 96 h and 2 weeks of infection.

Statistical analysis. Data were analyzed as previously described88 and expressed as the M ± SEM. Differences between groups were analyzed by non-paired Student’s t test or analysis of variance (ANOVA) followed by the Tukey test. Survival times differences were characterized using a LogRank test. Data were analyzed using GraphPad Prism 7.03 software (GraphPad Prism Software, Inc.). p values ≤ 0.05 were considered significant.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received: 28 February 2020; Accepted: 11 June 2020
Published online: 09 July 2020

References

1. Mandal, P. K. Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology. J. Comp. Physiol. B 175, 221–230 (2005).

2. Denison, M. S. & Nagy, S. R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 43, 309–334 (2003).

3. Stockinger, B., Di Meglio, P., Gialitakis, M. & Duarte, J. H. The aryl hydrocarbon receptor: multitasking in the immune system. Annu. Rev. Immunol. 32, 403–432 (2014).

4. Schrenk, D. Impact of dioxin-type induction of drug metalolizing enzymes on the metabolism of endo- and xenobiotics. Biochem. Pharmacol. 55, 1155–1162 (1998).

5. Nguyen, L. P. & Bradfield, C. A. The search for endogenous activators of the aryl hydrocarbon receptor. Chem. Res. Toxicol. 21, 102–116 (2008).

6. DiNatale, B. C. et al. Kynurenine acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol. Sci. 115, 89–97 (2010).

7. Apetoh, L. et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat. Immunol. 11, 854–861 (2010).

8. Kimura, A., Naka, T., Nohara, K., Fujii-Kuriyama, Y. & Kishimoto, T. Aryl hydrocarbon receptor regulates Stat1 activation and induced by IL-27. Proc. Natl. Acad. Sci. USA 105, 9721–9726 (2008).

9. Veldhoen, M. et al. The aryl hydrocarbon receptor links Th17-cell-mediated autoimmunity to environmental toxins. Nature 453, 106–109 (2008).

10. Quintana, F. J. et al. Control of T(reg) and Th(17) cell differentiation by the aryl hydrocarbon receptor. Nature 453, 65–71 (2008).

11. Nguyen, N. T., Hanhie, H., Nakahama, T. & Kishimoto, T. The roles of aryl hydrocarbon receptor in immune responses. Int. Immunol. 25, 333–343 (2013).

12. Lawrence, B. P. & Vorderstrasse, B. A. New insights into the aryl hydrocarbon receptor as a modulator of host responses to infection. Semin. Immunopathol. 35, 615–626 (2013).

13. Safe, S., Cheng, Y. & Jin, U. H. The aryl hydrocarbon receptor (AhR) as a drug target for cancer chemotherapy. Curr. Opin. Toxicol. 2, 24–29 (2017).

14. Vos, J. G., Kreeftenberg, J. G., Engel, H. W., Minderhoud, A. & Van Noorle Jansen, L. M. Studies on 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced immune suppression and decreased resistance to infection: endotoxin hypersensitivity, serum zinc concentrations and effect of thymosin treatment. Toxicology 9, 75–86 (1978).

15. Boule, L. A., Burke, C. G., Jin, G. B. & Lawrence, B. P. Aryl hydrocarbon receptor signaling modulates antiviral immune responses: ligand metabolism rather than chemical source is the stronger predictor of outcome. Sci. Rep. 8, 1826 (2018).

16. Moura-Alves, P. et al. AhR sensing of bacterial pigments regulates antibacterial defense. Nature 512, 387–392 (2014).

17. Bowers, O. J. et al. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) reduces Leishmania major burdens in C57BL/6 mice. Am. J. Trop. Med. Hyg. 75, 749–752 (2006).

18. Luebke, R. W. et al. Assessment of host resistance to *Trichinella spiralis* in mice following preinfection exposure to 2,3,7,8-TCDD. Toxicol. Appl. Pharmacol. 125, 7–16 (1994).

19. Bozza, S. et al. A crucial role for tryptophan catabolism at the host/Candida albicans interface. J. Immunol. 174, 2910–2918 (2005).

20. De Luca, A. et al. Functional yet balanced reactivity to *Candida albicans* requires TRIF, MyD88, and IDO-dependent inhibition of Rorc. J. Immunol. 17, 5999–6008 (2007).

21. Romaní, L., Zelante, T., De Luca, A., Fallarino, F. & Puccetti, P. IL-17 and therapeutic kynurenines in pathogenic inflammation to fungi. J. Immunol. 180, 5157–5162 (2008).
22. De Luca, A. et al. IL-22 defines a novel immune pathway of antifungal resistance. *Mucosal Immunol.* 3, 361–373 (2010).
23. Veldhoen, M., Hirota, K., Christensen, J., O’Garra, A. & Stockinger, B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. *J. Exp. Med.* 206, 43–49 (2009).
24. Esser, C., Rannug, A. & Stockinger, B. The aryl hydrocarbon receptor in immunity. *Trends Immunol.* 30, 447–454 (2009).
25. Eberl, G., Colonna, M., Di Santo, J. P. & McKenzie, A. N. Innate lymphoid cells: a new paradigm in immunology. *Science* 348, 637–6566 (2015).
26. Sawa, S. et al. Lineage relationship analysis of RORγt+ innate lymphoid cells. *Science* 333, 665–669 (2010).
27. Satoh-Takahayama, N. et al. Microbial flora drives interleukin 22 production in intestinal NKP46+ cells that provide innate mucosal immune defense. *Immunity* 29, 958–970 (2008).
28. Vivier, E. et al. Innate Lymphoid cells: 10 years on. *Cell* 174, 1054–1066 (2018).
29. Li, Y. et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. *Cell* 147, 629–640 (2011).
30. Nascimento, F., Calich, V. L. & Kalil, C. A. The aryl hydrocarbon receptor modulates cytokine and reactive oxygen species in macrophages and dendritic cells in vitro and in vivo. *J. Immunol.* 185, 1322–1332 (2010).
31. Vogel, C. E., Goeth, S. R., Dong, B., Pessah, I. N. & Matsumura, F. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. *Biochem. Biophys. Res. Commun.* 375, 331–335 (2008).
32. Mulero-Navarro, S. & Fernandez-Salgueiro, P. M. New trends in aryl hydrocarbon receptor biology. *Front. Cell Dev. Biol.* 4, 45 (2016).
33. Calich, V. L., Mamoni, R. L. & Loures, F. V. Regulatory T cells in paracoccidioidomycosis. *Immunol. Today* 38, 86–93 (2016).
34. Araújo, E. F. et al. Indoleamine 2,3-dioxygenase controls fungal loads and immunity in paracoccidioidomycosis but is more important to susceptible than resistant hosts. *PLoS Negl. Trop. Dis.* 8, e3330 (2014).
35. Felonato, M. et al. Lineage relationship analysis of RORγt+ innate lymphoid cells. *J. Immunol.* 185, 1390–1399 (2010).
36. Bessede, A. et al. Aryl hydrocarbon receptor control of a disease tolerance defense pathway. *Nature* 511, 184–190 (2014).
37. Montagnoli, C. et al. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. *J. Immunol.* 176, 1712–1723 (2006).
38. Zelante, T. et al. Tryptophan feeding of the IDO1-AhR axis in host-microbial symbiosis. *Front. Immunol.* 5, 640 (2014).
39. Mehr, A. et al. Tryptophan catabolism in the gut. *J. Innate Immun.* 7, 672–682 (2015).
40. Veldhoen, M. et al. IL-22 defines a novel immune pathway of antifungal resistance. *Mucosal Immunol.* 3, 361–373 (2010).
41. Misharin, A. V. et al.Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. *Am. J. Respir. Cell Mol. Biol.* 49, 503–510 (2013).
42. Huntington, N. D., Carpentier, S., Vivier, E. & Belz, G. T. Innate lymphoid cells: parallel checkpoints and coordinate interactions with T cells. *Curr. Opin. Immunol.* 38, 86–93 (2016).
43. Hirahara, K. & Nakayama, T. CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. *Int. Immunol.* 28, 163–171 (2016).
44. Vogel, C. E., Goeth, S. R., Dong, B., Pessah, I. N. & Matsumura, F. Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. *Biochem. Biophys. Res. Commun.* 375, 331–335 (2008).
45. Muller, A. L. & Munn, D. H. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?. *Immunol. Today* 20, 469–473 (1999).
46. Fallarino, F. et al. Tryptophan catabolism generates autoimmune-preventive regulatory T cells. *Transpl. Immunol.* 17, 58–60 (2006).
47. Mezrich, J. D. et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. *J. Immunol.* 185, 3190–3198 (2010).
48. Bessede, A. et al. Aryl hydrocarbon receptor control of a disease tolerance defense pathway. *Nature* 511, 184–190 (2014).
49. Montagnoli, C. et al. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. *J. Immunol.* 176, 1712–1723 (2006).
50. Zelante, T. et al. Tryptophan feeding of the IDO1-AhR axis in host-microbial symbiosis. *Front. Immunol.* 5, 640 (2014).
51. Barros, A. et al. The aryl hydrocarbon receptor modulates production of cytokines and reactive oxygen species and development of myocarditis during Trypanosoma cruzi infection. *Infect. Immun.* 84, 3071–3082 (2016).
52. Tavares, A. H. et al. NLRP3 inflammasome activation by Paracoccidioides brasiliensis. *PLoS Negl. Trop. Dis.* 7, e2595 (2013).
53. Ketelut-Carneiro, N. et al. IL-18 triggered by the Nlrp3 inflammasome induces host innate resistance in a pulmonary model of fungal infection. *J. Immunol.* 194, 4507–4517 (2015).
54. Ferrarotti, C. et al. Expression of decin-1 and enhanced activation of NALP3 inflammasomes are associated with resistance to paracoccidioidomycosis. *Front. Microbiol.* 6, 913 (2015).
55. Ferrarotti, C. et al. NOD-like receptor P3 inflammasomes controls protective Th1/Th17 immunity against pulmonary paracoccidioidomycosis. *Front. Immunol.* 8, 786 (2017).
56. Hughes, T. et al. Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. *Immunity* 32, 803–814 (2010).
57. Guo, X. et al. Innate Lymphoid Cells control early colonization resistance against intestinal pathogens through ID2-dependent regulation of the microbiota. *Immunity* 42, 731–743 (2015).
58. Basu, R. et al. Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria. *Immunity* 37, 1061–1075 (2012).
59. Wahl, S. M., Wen, J. & Moutsopoulos, N. TGF-beta: a mobile purveyor of immune privilege. *Immunol. Rev.* 213, 213–227 (2006).
60. Awasthi, A. et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. *Nat. Immunol.* 8, 1380–1389 (2007).
61. Stumhofer, J. S. et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. *Nat. Immunol.* 7, 937–945 (2006).
62. Aparicio-Siegmund, S. & Garbers, C. The biology of interleukin 27 reveals unique pro- and anti-inflammatory functions in immunity. *Cytokine Growth Factor Rev.* 26, 579–586 (2015).
63. Borghi, M. et al. Targeting the aryl hydrocarbon receptor with indole-3-aldehyde protects from vulvovaginal candidiasis via IL-22-IL-18 cross-talk. *Front. Immunol.* 10, 2364 (2019).
64. Zelante, T. et al. Tryptophan catabolism from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Immunity* 39, 372–385 (2013).
65. Bazan, S. B. et al. Loss- and Gain-of-Function Approaches Indicate a Dual Role Exerted by Regulatory T Cells in Pulmonary Paracoccidioidomycosis. *PLoS Negl. Trop. Dis.* 9, e0004189 (2015).
68. Galdino, N. A. L. et al. Depletion of regulatory T cells in ongoing paracoccidioidomycosis rescues protective Th1/Th17 immunity and prevents fatal disease outcome. Sci Rep. 8, 16544 (2018).
69. Schmidt, J. V., Su, G. H., Reddy, J. K., Simon, M. C. & Bradfield, C. A. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc. Natl. Acad. Sci. USA 93, 6731–6736 (1996).
70. Singer-Vermes, L. M., Caldeira, C. B., Burger, E. & Calich, V. L. Experimental murine paracoccidioidomycosis: relationship among dissemination of the infection, humoral and cellular responses. Clin. Exp. Immunol. 94, 75–79 (1993).
71. Cano, L. E., Singer-Vermes, L. M., Vaz, C. A., Russo, M. & Calich, V. L. Pulmonary paracoccidioidomycosis in resistant and susceptible mice: relationship among progression of infection, bronchoalveolar cell activation, cellular immune response, and specific isotype patterns. Infect. Immun. 63, 1777–1783 (1995).
72. Loures, F. V. et al. MyD88 signaling is required for efficient innate and adaptive immune responses to Paracoccidioides brasiliensis infection. Infect. Immun. 79, 2470–2480 (2011).
73. Kim, S. H. et al. Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol. Pharmacol. 6, 1871–1878 (2006).

Acknowledgements
We are grateful to Tânia A. Costa for her invaluable technical assistance. We thank Paulo Albe for processing the histological samples. This work was supported by a grant from the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP-grant to VLG 2011/51258-2 and 2016/23189-0; fellowship to EFA 2014/18668-2; grant to FVL 2018/14762-3; fellowship to NWP 2019-09278-8), European Union H2020 ERA project (No 667824 – EXCELtoINNOV) to MV and Conselho Nacional de Pesquisas (CNPq).

Author contributions
E.F.A. and V.L.G.C. conceived and planned the experiments. E.F.A, N.W.P. and F.V.L. carried out the experiments. M.V. contributed to the interpretation of the results. E.F.A., F.V.L. and V.L.G.C. wrote the manuscript. E.F.A., F.V.L. and N.W.P. prepared the figures. V.L.G.C. supervised the project. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-68322-6.

Correspondence and requests for materials should be addressed to V.L.G.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020